Ticker League

EBITDA for Alnylam Pharmaceuticals (ALNY)

Latest filings through · Reported

Metric

TTM

$772.35M

YoY change

-453.1%

5Y CAGR

—

Peak year (2025)

$631.44M

EBITDA history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: $631.44M

EBITDA growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: -453.1%

EBITDA history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

  • 2025$631.44M-453.1%
  • 2024−$178.85M-30.7%
  • 2023−$258.24M-72.1%
  • 2022−$926.56M+40.1%
  • 2021−$661.56M-10.2%
  • 2020−$736.33M-15.2%
  • 2019−$868.08M+15.1%
  • 2018−$754.24M+54.5%
  • 2017−$488.19M+19.2%
  • 2016−$409.46M+47.8%
  • 2015−$276.96M+60.8%
  • 2014−$172.29M+108.3%
  • 2013−$82.71M+59.9%
  • 2012−$51.71M+4.1%
  • 2011−$49.69M+30.6%
  • 2010−$38.06M-7.2%
  • 2009−$41.02M+116.6%
  • 2008−$18.93M-74.8%
  • 2007−$75.06M+110.3%
  • 2006−$35.69M-8.1%
  • 2005−$38.83M+31.4%
  • 2004−$29.55M+50.7%
  • 2003−$19.61M+368.5%
  • 2002−$4.19M—

EBITDA values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Alnylam Pharmaceuticals (ALNY)

According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $772.35M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

Alnylam Pharmaceuticals (ALNY) most recent annual EBITDA stands at $631.44M (2025) – plunged 453.1% year-over-year.

Across the available history, EBITDA reached its high of $631.44M in 2025 and its low of −$926.56M in 2022.

Alnylam Pharmaceuticals EBITDA by Year

Alnylam Pharmaceuticals EBITDA 2025: $631.44M

Alnylam Pharmaceuticals EBITDA in 2025 was $631.44M, plunged 453.1% below 2024. This figure represents the highest annual value in the available history.

Alnylam Pharmaceuticals EBITDA 2024: −$178.85M

2024's EBITDA for Alnylam Pharmaceuticals came in at −$178.85M, plunged 30.7% below 2023.

Alnylam Pharmaceuticals EBITDA 2023: −$258.24M

Alnylam Pharmaceuticals posted EBITDA of −$258.24M in 2023, plunged 72.1% below 2022.

Alnylam Pharmaceuticals EBITDA 2022: −$926.56M

In 2022, Alnylam Pharmaceuticals reported EBITDA of −$926.56M, surged 40.1% from 2021. This figure represents the lowest annual value in the available history.

Alnylam Pharmaceuticals EBITDA 2021: −$661.56M

Alnylam Pharmaceuticals EBITDA in 2021 was −$661.56M.

See more financial history for Alnylam Pharmaceuticals (ALNY).

Sector peers by EBITDA

Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest EBITDA

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return